Who are TAS-102, Regorafenib , Fruquintinib's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tas-102-regorafenib-fruquintinib.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

TAS-102, Regorafenib , Fruquintinib — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TAS-102, Regorafenib , Fruquintinib (TAS-102, Regorafenib , Fruquintinib) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside analog, Multi-kinase inhibitor, VEGFR2 inhibitor. Area: Oncology.

phase 3 Nucleoside analog, Multi-kinase inhibitor, VEGFR2 inhibitor Thymidylate synthase, VEGFR2 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

TAS-102, Regorafenib , Fruquintinib (TAS-102, Regorafenib , Fruquintinib) — Suzhou Suncadia Biopharmaceuticals Co., Ltd.. TAS-102 is a nucleoside analog that inhibits thymidylate synthase, leading to DNA damage in cancer cells. Regorafenib is a multi-kinase inhibitor that targets angiogenic, stromal, and tumor cells. Fruquintinib is a potent and highly selective inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2).

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
TAS-102, Regorafenib , Fruquintinib TARGET	TAS-102, Regorafenib , Fruquintinib	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	phase 3	Nucleoside analog, Multi-kinase inhibitor, VEGFR2 inhibitor	Thymidylate synthase, VEGFR2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside analog, Multi-kinase inhibitor, VEGFR2 inhibitor class)

Suzhou Suncadia Biopharmaceuticals Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TAS-102, Regorafenib , Fruquintinib — Competitive Intelligence Brief. https://druglandscape.com/ci/tas-102-regorafenib-fruquintinib. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab